Business

Announcement on Voluntary Disclosure of YKYY017 Aerosol Inhalation Formulation Receiving FDA Clinical Trial Approval for the Indication of Prophylaxis and Treatment of Coronavirus-Associated Respiratory Infections

Announcement on Voluntary Disclosure of YKYY017 Aerosol Inhalation Formulation Receiving FDA Clinical Trial Approval for the Indication of Prophylaxis and Treatment of Coronavirus-Associated Respiratory Infections

articleYoucare Pharmaceutical Group Co. Ltd. Class AJune 26, 20264/news/announcement-on-voluntary-disclosure-of-ykyy017-aerosol-inhalation-formulation-receiving-fda-clinical-trial-approval-for-the-indication-of-prophylaxis-and-treatment-of-coronavirus-associated-respiratory-infections
Announcement on Voluntary Disclosure of YKYY017 Aerosol Inhalation Formulation Receiving FDA Clinical Trial Approval for the Indication of Prophylaxis and Treatment of Coronavirus-Associated Respiratory Infections

About this update from Youcare Pharmaceutical Group Co. Ltd. Class A

Announcement on Voluntary Disclosure of YKYY017 Aerosol Inhalation Formulation Receiving FDA Clinical Trial Approval for the Indication of Prophylaxis and Treatment of Coronavirus-Associated Respiratory Infections The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Youcare Pharmaceutical Group Co. Ltd. Class A